[
  {
    "ts": null,
    "headline": "NYLI Balanced Fund Q1 2025 Commentary",
    "summary": "The NYLI Balanced Fund outperformed its benchmark only marginally this quarter but landed solidly amongst the top quartile of funds within Morningstarâs Moderate Allocation category.",
    "url": "https://finnhub.io/api/news?id=af9090335462de0ade490b12852e111498cc7938f55c80e909064d6a99404ca0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751586300,
      "headline": "NYLI Balanced Fund Q1 2025 Commentary",
      "id": 135743781,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2201143780/image_2201143780.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The NYLI Balanced Fund outperformed its benchmark only marginally this quarter but landed solidly amongst the top quartile of funds within Morningstarâs Moderate Allocation category.",
      "url": "https://finnhub.io/api/news?id=af9090335462de0ade490b12852e111498cc7938f55c80e909064d6a99404ca0"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again",
    "summary": "Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=2de2aea23b0a91001f85e45538c5aae0a650a8f54611f441c7c1e1130fe26c7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751559001,
      "headline": "Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again",
      "id": 135743981,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=2de2aea23b0a91001f85e45538c5aae0a650a8f54611f441c7c1e1130fe26c7f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finnhub.io/api/news?id=155ca395776587894348d1f95f90a49c2942dde3f149184b6bfeda86edbd8c79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751557504,
      "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice",
      "id": 135743982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=155ca395776587894348d1f95f90a49c2942dde3f149184b6bfeda86edbd8c79"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, The Home Depot, Micron Technology, Autoscope Technologies and Nova LifeStyle",
    "summary": "JNJ, HD, MU, AATC, and NVFY stand out with strong gains and strategic shifts amid macro headwinds and evolving consumer demand.",
    "url": "https://finnhub.io/api/news?id=fbdb6338e4d73bde3a976c7a01bf88adadf42bef572cb87e73e10dc93f32de4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751547780,
      "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, The Home Depot, Micron Technology, Autoscope Technologies and Nova LifeStyle",
      "id": 135735529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ, HD, MU, AATC, and NVFY stand out with strong gains and strategic shifts amid macro headwinds and evolving consumer demand.",
      "url": "https://finnhub.io/api/news?id=fbdb6338e4d73bde3a976c7a01bf88adadf42bef572cb87e73e10dc93f32de4e"
    }
  },
  {
    "ts": null,
    "headline": "Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?",
    "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=af7c046b80af6b78a87665127dd5114b2f758ac8f07107d29b2a4fa95ae9054f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751547603,
      "headline": "Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?",
      "id": 135735531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=af7c046b80af6b78a87665127dd5114b2f758ac8f07107d29b2a4fa95ae9054f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations",
    "summary": "The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of care, abiraterone acetate plus prednisone or prednisolone1 The results demonstrate significant and clinically meaningful benefits of the niraparib and abiraterone acetate plus prednisone or prednisolone regimen in delaying cancer progression and worsening of symptoms1 BEERSE, BELGIUM, July 03, 2025 (GLOB",
    "url": "https://finnhub.io/api/news?id=e00e2ef3dd270dc22db3a2fcb47d4ecab44564dee89647843c94cdae5c1b229a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751546460,
      "headline": "Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations",
      "id": 135735534,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of care, abiraterone acetate plus prednisone or prednisolone1 The results demonstrate significant and clinically meaningful benefits of the niraparib and abiraterone acetate plus prednisone or prednisolone regimen in delaying cancer progression and worsening of symptoms1 BEERSE, BELGIUM, July 03, 2025 (GLOB",
      "url": "https://finnhub.io/api/news?id=e00e2ef3dd270dc22db3a2fcb47d4ecab44564dee89647843c94cdae5c1b229a"
    }
  },
  {
    "ts": null,
    "headline": "MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE",
    "summary": "Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.",
    "url": "https://finnhub.io/api/news?id=0dd18af311cd9a7e7ae84482050a885bb1913339fd6b10da65693d99733b4171",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751545800,
      "headline": "MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE",
      "id": 135735537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.",
      "url": "https://finnhub.io/api/news?id=0dd18af311cd9a7e7ae84482050a885bb1913339fd6b10da65693d99733b4171"
    }
  },
  {
    "ts": null,
    "headline": "Globus Medical: Obtaining My Backing Again",
    "summary": "Globus Medical shares have reset after a soft Q1 and Nevro acquisition, making valuations more attractive despite near-term dilution. Read the full GMED stock analysis.",
    "url": "https://finnhub.io/api/news?id=71099eb95bbde3c97e081ab43a0cb4778dea5ba855839f3e96a3dd49ebadb029",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751544630,
      "headline": "Globus Medical: Obtaining My Backing Again",
      "id": 135738284,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1860536835/image_1860536835.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Globus Medical shares have reset after a soft Q1 and Nevro acquisition, making valuations more attractive despite near-term dilution. Read the full GMED stock analysis.",
      "url": "https://finnhub.io/api/news?id=71099eb95bbde3c97e081ab43a0cb4778dea5ba855839f3e96a3dd49ebadb029"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma",
    "summary": "Lynozyfic can be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.",
    "url": "https://finnhub.io/api/news?id=7094989b37f7b267947e1092daa23c9e4b17471a9fea1376c7e624f1441b13b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751543043,
      "headline": "Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma",
      "id": 135735538,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Lynozyfic can be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.",
      "url": "https://finnhub.io/api/news?id=7094989b37f7b267947e1092daa23c9e4b17471a9fea1376c7e624f1441b13b0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations",
    "summary": "Janssen-Cilag International NV, a Johnson & Johnson company, today announced the submission of an extension of indication application to the European Medicines Agency seeking approval of AKEEGA® ...",
    "url": "https://finnhub.io/api/news?id=8c8005eae9cf409c513224c78ac92526a203dea1722e92dc33d15a429b8c5f27",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751537287,
      "headline": "Johnson & Johnson : submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations",
      "id": 135733246,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Janssen-Cilag International NV, a Johnson & Johnson company, today announced the submission of an extension of indication application to the European Medicines Agency seeking approval of AKEEGA® ...",
      "url": "https://finnhub.io/api/news?id=8c8005eae9cf409c513224c78ac92526a203dea1722e92dc33d15a429b8c5f27"
    }
  }
]